BioSpace News Archive

Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.

October 25, 2022
·
4 min read
Biotech Bay

Keynote Speakers from Medtronic and Ketryx Corporation Taking the Stage at BIOMEDevice Silicon Valley

BIOMEDevice Silicon Valley, the must-attend regional show connecting engineers and cutting-edge medtech companies, today announces registration is now live for November.

October 25, 2022
·
4 min read
Business

Enveda Biosciences appoints industry leader Mark Deeg, M.D., Ph.D., as Chief Medical Officer

Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the company’s Chief Medical Officer.

October 25, 2022
·
4 min read
Business

Arcutis to Report Third Quarter Financial Results

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 5:00 p.m. ET on Tuesday, November 8, 2022, to report its third quarter financial results.

October 25, 2022
·
2 min read
Lone Star Bio

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock - October 25, 2022

Taysha Gene Therapies, Inc. announced that it intends to offer and sell, subject to market conditions, $30 million of shares of its common stock in an underwritten public offering.

October 25, 2022
·
4 min read